Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Advanced Technological Solutions for X band Earth Observation Systems (ATOS)

Framework: Horizon 2020 — Industrial Leadership
Programme: Space
Theme: Enabling European competitiveness, non-dependence and innovation of the European space sector
Action type: Research and Innovation actions
Countries involved: Italy,Germany,Italy,Italy,Switzerland
Call: Competitiveness in Earth observation mission technologies (H2020-COMPET-2017, 2017)
Start date: 2018-01-01
End date: 2021-05-31
Duration (months): 41.0
Total project cost (EUR): 2568110.0
EU funding (EUR): 2568110.0
Participants: 5
Project status: CLOSED

The ATOS project will develop and qualify a new generation of X band T/R modules, based on GaN HEMT and SiGe BiCMOS technology, with innovative packaging techniques that minimize the footprint, and will integrate a set of T/R modules in a demonstrator of a high-efficiency densely populated AESA tile to be verified in radiated tests. Such development will enable future space-borne AESA radars at X band with at least a 3x leap in bandwidth, power density and/or azimuth steering capability with respect to current SAR AESAs developed in Europe, and will also enable or drastically improve compact solutions based on array-fed large unfurlable reflectors on small platforms. The ATOS project will build or consolidate a fully European supply chain including semiconductor technology providers, SMEs and academia as design centers and test houses, and a large enterprise as integrator of space-grade equipment up to turnkey space systems. The components of such team will broaden the scope of their competences through the project, enabling them to be candidates for future developments in related projects and applications in commercial space as well as institutional programs. The ATOS advancements achieved will be disseminated to foster initiatives of new mission concepts and business opportunities, specifically but not limited to Earth Observation, for which results of the project may represent a key technology enabler.

Keywords: active antennas,transmit,receive modules,gan power amplifier,sige bicmos core chip
PReparing Introduction to MArket of SKOTI (PRIMASKOTI) - a breakthrough solution for real-time studies of cytoskeletal motors at single-molecule resolution (PRIMASKOTI)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Germany
Call: ERC-Proof of Concept-2016 (ERC-2016-PoC, 2016)
Start date: 2017-08-01
End date: 2019-01-31
Duration (months): 18.0
Total project cost (EUR): 149238.0
EU funding (EUR): 149238.0
Participants: 1
Project status: CLOSED

The PRIMASKOTI project will prepare the commercialization of SKOTI—the Swiss Knife for Optical Tweezers and Imaging. The scientific instrument SKOTI is designed to measure interactions between single biomolecules with a focus on cytoskeletal molecular machines. SKOTI combines several state-of-the-art microscopy techniques with contact-less mechanical manipulation, so-called optical tweezers. Because of its ultra high stability, SKOTI has its particular strengths in experiments requiring a solid support such as a glass surface. This requirement is often the case for cytoskeletal motor protein studies. Since these molecular machines are key to many essential cellular processes such as transport or cell division, being able to study their interactions is an important step towards understanding diseases such as cancer or neurodegeneration. However, due to the highly specialized knowledge necessary to build and operate such instruments, hardly commercially available, single-molecule experiments are difficult. By commercializing SKOTI, we aim to provide a simple-to-access tool which will broaden the scope of applications and users. SKOTI will provide a modular microscope and optical manipulation platform with unprecedented force- and displacement-resolution, ease of operation through motorization and automatization, flexibility, and overall stability of the system. The key idea is to commercialize a complete solution, where the instrument is supplemented with an isolation from the environment, operation and analysis software, specialized probes, service contracts, and kits for experiments that help to minimize preparation times. This approach will simplify single-molecule experiments, increase throughput, and lower barriers to engage in such studies. In the long term, our novel, cutting-edge research tool for life sciences will provide insight to essential cellular processes and pave the way for new medical approaches.

Keywords: life sciences,biophysics,optical tweezers,single molecule,force spectroscopy,high resolution,motor protein,membrane proteins,scientific instrument,fluorescence microscopy
nonlineAr Multimode and mUlticore optical fiberS for multIple appliCations (AMUSIC)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: United Kingdom
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2015, 2015)
Start date: 2016-09-15
End date: 2018-09-14
Duration (months): 24.0
Total project cost (EUR): 195454.8
EU funding (EUR): 195454.8
Participants: 1
Project status: CLOSED

Light propagation in multimode (MM) and multicore (MC) optical fibers is rapidly emerging as one of the most exciting topics in optical physics. These fibers are employed in several fields, spanning from telecommunications to spectroscopy and astronomy. In addition, they support a complex nonlinear spatiotemporal dynamics that is the subject of intense research and the understanding of which is far from being complete. It is in this framework that the project AMUSIC arises: it aims to advance the state-of-art understanding of nonlinear effects in MM and MC fibers and to investigate some promising devices where these effects are exploited in view of important applications in several key-areas. The first part of the project is dedicated to the development of an optimized numerical platform for the analysis of nonlinear effects in MM and MC fibers. In the second part we target the investigation and experimental implementation of the following fiber based devices: 1)MM fiber optical parametric amplifiers and oscillators supporting the simultaneous amplification/generation of several modes in an extremely broad and tunable band. 2) High power MC- and MM-doped fiber lasers, where nonlinear effects are exploited to promote phase-synchronization and multimode soliton mode-locking. AMUSIC is aligned with the key-drivers and focus areas of Horizon-2020 Work program (WP) . The project goals will be achieved in the framework of international academic and industrial partnerships (WP key-drivers : "Leverage and boost engagement of industry" and "Supporting strong partnership with Member States"). In addition, the envisaged devices may find application in several fields, among which molecular fingerprinting techniques for personalised detection of disease by breath analysis (WP focus area : "Personalising health and care") and Spatial-Division-Multiplexing schemes for new smart and sustainable digital infrastructures (WP focus area “Smart cities and communities”)

Keywords: multimode fibers,multimode fiber optical parametric amplifiers and oscillators,multimode and multicore lasers,numerical simulations,fiber design,nonlinear self organization
Psychiatric Disorders: ATX-inhibiting drugs as a new therapeutic option: Proof-of-Concept (PsychAID)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Panel: Neuroscience and Disorders of the Nervous System
Panel description: Nervous system development, homeostasis and ageing, nervous system function and dysfunction, systems neuroscience and modelling, biological basis of cognitive processes and of behaviour, neurological and mental disorders
Countries involved: Germany
Call: ERC Proof of Concept Grant (ERC-2018-PoC, 2018)
Start date: 2019-01-01
End date: 2020-12-31
Duration (months): 24.0
Total project cost (EUR): 149375.0
EU funding (EUR): 149375.0
Participants: 1
Project status: CLOSED

Within the frame of the ERC LiPsyD we have shown that recently discovered that the phospholipid LPA acts as a synaptic modulator playing a major role in regulating cortical excitability and being involved in psychiatric disorders (Trimbuch et al., 2009; Unichenko et al., 2016; Vogt et al., 2016; Vogt et al., 2017). Using specific small molecule inhibitors like PF8380, which target the LPA-synthesizing molecule autotaxin (ATX), we were able to decrease cortical hyperexcitability and to rescue disease-specific behavior in different animal models for schizophrenia to wild type (WT) levels. These results generated within the ERC LiPsyD demonstrate that ATX-inhibition is effective in treating psychiatric disorders (Vogt et al., 2016). Since current therapy for schizophrenia targeting cortical hyperexcitability is not available, ATX-inhibitors which act on excitatory neurotransmission and are effective in treating psychiatric disorders have a huge commercial potential in this 120 billion euro market (Olesen et al., 2012). To proceed towards the commercial application of ATX-inhibitors, the PI has teamed up with Merck and was granted a patent for the use of ATX-inhibitors for brain disorders (WO 2017/071799). Briefly, the patent covers the use of the ATX-inhibitors for the therapy of brain diseases (covering psychiatric disorders like schizophrenia and eating disorders but also cerebrovascular disorders) and the use of a latest generation of ATX-inhibitors (MSC 2285264 and MSC2358829), which are comparable to the most potent currently available ATX-inhibitors, are suitable for in-vivo application and have a positive toxicological profile. However, before starting clinical trials, the pharmacological profile and the effectiveness of the novel ATX inhibitors for treatment of psychiatric disorders have to be assessed. This PoC aims therefore to the preclinical characterization of these ATX-inhibitors which is a critical step towards their commercialization

Keywords: psychiatric disorders,schizophrenia,bioactive phospholipids,synapse,atx inhibitors,animal models
Plasticity of perceptual space under sensorimotor interactions (PLATYPUS)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Action type: Marie Skłodowska-Curie actions
Countries involved: Germany
Call: MSCA Special Needs Allowance (H2020-IBA-MSCA-SNLS-2019, 2019)
Start date: 2020-10-01
End date: 2023-04-30
Duration (months): 31.0
Total project cost (EUR): 31385.0
EU funding (EUR): 31385.0
Participants: 1
Project status: CLOSED

The Marie Skłodowska-Curie actions pay particular attention to physical accessibility and inclusion and foresee financial support for the additional costs entailed by recruited or seconded researchers/staff members with disabilities. This grant will cover the additional costs that the staff member with disabilities faces due to the increased mobility costs.

Keywords: eye movements,visual perception,perception and action
Understanding phase behaviour in plant proteins for large scale production of films and microcapsules (ScalePlantProt)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Society and Enterprise panel
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2021-08-02
End date: 2023-11-07
Duration (months): 24.0
Total project cost (EUR): 212933.76
EU funding (EUR): 212933.76
Participants: 1
Project status: SIGNED

Drawing on the expertise from the Experienced Researcher, this MSCA application aims to significantly advance the understanding of phase behaviour in plant proteins, to enable development of two primary products for sustainable plastic replacement, microcapsules and thermoplastic flexible films. Currently, large-scale production of plant protein based plastic alternatives is hampered by a lack of advanced knowledge of the phase behaviour of plant proteins. This research programme thus aims to for the first time systematically investigate the key phase transition of plant proteins — thermal phase transition and phase separation. This objective will be achieved by uniting two sets of skills: i) the Experienced Researcher’s expertise in plant protein self-assembly and ii) specialized knowledge of chemists, engineers and business management at Xampla Ltd for the commercially successful application of plant protein materials. The breakthrough aspect will be uniting traditional polymer science regarding phase transition and molecular understanding of proteins – the obtained materials can be manufactured using established industrial platform used for polymer processing. The approach thus makes the products competitive with current bio-based polymeric materials in market, or even synthetic plastic materials. Therefore, the research program will boost the European green-material market and addresses the Horizon 2020 societal and economic challenges.

Keywords: plant proteins,thermoplastic processing,phase separation,self assembled materials,scalable processing
Cost-Efficient Methods and Processes for Safety Relevant Embedded Systems (CESAR)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Embedded Computing Systems
Action type: Collaborative project
Partnership: ARTEMIS (Art-185)
Countries involved: Austria,Germany,France,Norway,Sweden,Germany,Spain,Italy,France,United Kingdom,Greece,France,Italy,Portugal,France,Germany,Germany,Italy,Spain,Germany,Austria,Sweden,Germany,France,United Kingdom,United Kingdom,Sweden,France
Call:  (ARTEMIS-2008-1, 2008)
Start date: 2009-03-01
End date: 2012-06-30
Duration (months): 40.0
Total project cost (EUR): 58300757.06
EU funding (EUR): 9736226.43
Participants: 53
Project status: CLOSED

The embedded safety-critical systems design and development industry is facing increasing complexity and variety of systems and devices, coupled with increasing regulatory constraints while costs, performances and time to market are constantly challenged. This has led to a profusion of enablers (new processes, methods and tools), which are neither integrated nor interoperable because they have been developed more or less independently, addressing only a part of the complexity issue, such as safety. The absence of internationally recognized open standards is a limiting factor in terms of industrial performance when com-panies have to select among these enablers. CESAR will bring significant and conclusive innovations in the two most improvable systems engineering disciplines: - Requirements engineering in particular through formalization of multi viewpoint and multi criteria requirements, - Component based engineering applied to design space exploration comprising multi-view/multi-criteria architecture trade-offs. In addition CESAR intends to provide industrial companies with a breakthrough in system development by deploying a customizable systems engineering ‘Reference Technology Plat-form’ (RTP) making it possible to integrate or interoperate existing or emerging available technologies. This will be a significant step forward in terms of industrial performance im-provement that will help to establish de-facto standards and contribute to the standardization effort from a European perspective. Relying on industrial use-cases and scenarios, CESAR is strongly industry driven. It will ad-dress societal safety, mobility and environmental demands from a multi-domain point of view, relying on high maturity inputs (TRL 4) and target high maturity outputs (TRL 6). Quantified objectives are defined in the proposal regarding integration aspects (RTP), processes and product- related aspects.

Keywords: technology platform,new processes,methods and tools,interoperating technologies
Understanding chronic pain and improving its treatment (EUROPAIN)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Denmark,United Kingdom,United Kingdom,Germany,Germany,Germany,Germany,Germany,Denmark,Denmark,Denmark,Germany,Spain,Belgium,France,Sweden,Germany,Netherlands,Germany
Call:  (IMI-JU-01-2008, 2008)
Start date: 2009-10-01
End date: 2015-09-30
Duration (months): 72.0
Total project cost (EUR): 22550083.0
EU funding (EUR): 6229343.0
Participants: 26
Project status: CLOSED

We will establish an international team of leading researchers and clinicians (EuroPain) to undertake multidisciplinary translational research which will: 1) increase the understanding of chronic pain mechanisms; 2)facilitate the development of novel analgesic drugs; and 3) improve the treatment of chronic pain patients. Nineteen researchers drawn from the London Pain Consortium, the Danish Pain Research Centre, the German Pain Network and a Spanish research-intensive SME centre will form a ‘meta’ consortium with complementary expertise. The LPC is mainly laboratory based with a spectrum of skills from molecular biology and bioinformatics through integrated research in animal models to human physiological research, including imaging.The German and Danish groups have large databases on neuropathic and postsurgical pain, respectively, while the Spanish centre offers expertise in human microneurography. We will undertake a series of six interlinked and mutually supportive programs of experimental research, underpinned and supported by a coordinated training and bioinformatics facility. These programs will form a series of workpackages each delivered through collaboration of network laboratories to bring together multiple techniques and considerable expertise to each area. In addition, there will be considerable synergies between the programs. The programs, which fully address the Call, will focus on: Neurobiological mechanisms of chronic pain; Improving animal models of pain; Translational pain models in humans; Mechanisms and assessment of pain in patients; Risk factors for chronic pain.

Keywords: europain
Novel Methods leading to New Medications in Depression and Schizophrenia (NEWMEDS)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Denmark,United Kingdom,Sweden,United Kingdom,Germany,Spain,Iceland,Germany,Belgium,Switzerland,Finland,France,Israel,Germany
Call:  (IMI-JU-01-2008, 2008)
Start date: 2009-09-01
End date: 2015-02-28
Duration (months): 66.0
Total project cost (EUR): 24849675.0
EU funding (EUR): 8986216.0
Participants: 21
Project status: CLOSED

Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are few novel treatments. We think this is because of three major “bottle-necks”: a lack of etiologically-driven or pathophysiologically-accurate animal models; a lack of tests that provide indication of efficacy in healthy volunteers; and the reliance of clinical trials on DSM categories which provide a collection of biologically heterogeneous patients. Our broad working hypothesis is that a focus on cross-species endophenotypes, testing in healthy volunteers and finding biologically-homogenous groups of patients will overcome existing limitations in target identification, early triage and clinical trials. To implement this idea six leading European institutions and two SMEs will partner with the EFPIA to: a) develop animal models that carry confirmed genetic risks, and in these animals to focus on cross-species endophenotypes (e.g., cognitive function, electrophysiology) to facilitate new drug discovery; b) validate the use of fMRI-based endopheno types in genetically-selected healthy volunteers and patients as early and surrogate markers for efficacy; and to combine this with PET approaches for plasma-kinetics to brain-dynamics modelling to provide guidance regarding optimal clinical trial design; and c) identify pharmacogenetic and multi-omic biomarkers that can be used to stratify patients within an umbrella DSM-diagnosis, thus allowing for ) targeted clinical trials, individualized treatment and back-translation of subgroup-specific biomarkers into preclinical drug discovery. To increase the chance of a breakthrough we will implement new analytical approaches (e.g. support vector machine learning algorithms; Bayesian analyses) and will actively collaborate with other ongoing international efforts (esp. the Biomarkers Consortium, NIH).

Keywords: newmeds
Physical Activity as a Crucial Patient Reported Outcome in COPD (PRO- ACTIVE)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Italy,Belgium,United Kingdom,United Kingdom,Spain,Switzerland,Netherlands,Netherlands,Sweden,Belgium,Germany,Greece,United Kingdom
Call:  (IMI-JU-01-2008, 2008)
Start date: 2009-09-01
End date: 2016-05-31
Duration (months): 81.0
Total project cost (EUR): 15635822.0
EU funding (EUR): 6767597.0
Participants: 20
Project status: CLOSED

Physical activity (PA) is essential in maintaining optimal health in chronic diseases, including COPD.More physically active patients have less hospital admissions and better survival. Validated physicalactivity monitors have become available in recent years, and together with patient report of symptomsand distress of physical (in)activity, this may form a potent new Patient Reported Outcome (PRO) in COPD.In response to the IMI-call this consortium will develop and validate two PRO’s. In phase 1, items for the PRO will be generated based on input from an updated literature survey, expert opinion and patients. One PRO investigates PA on a daily basis, using a user friendly interface. This allows investigating the impact of exacerbations and the dynamics of improvement after initiating treatment. A second PRO is used during clinical trial visits. A unique feature of the PRO’s is that they will include unobtrusive physical activity monitoring. Validity, reproducibility, responsiveness and minimally clinically meaningful difference of the PRO’s will be investigated. The new PRO’s will be put in thecontext of other, more conventional outcomes. using path-analysis and structural equational modeling.Development will be in compliance to the guidelines of the FDA and in collaboration with EMEA.Iii phase 2 the PRO’s will be used in 3 large multi-center clinical trials. These trials will contribute tothe validity and health economic value of the PRO’s. They tackle contemporary questions in COPDcare, including pharmacotherapy, PA counseling and pulmonary rehabilitation.The consortium is well equipped to develop PRO’s. It includes academic centers with a solid reputationin COPD research, centers with expertise in epidemiology, experts in conducting systematic reviews,PRO-methodology and statistics. Patient associations are in the core of the consortium. A SME willdevelop patient material in various languages.

Keywords: pro-active